Thomas A. Burke, PharmD, MPH

home / authors / thomas-a-burke-pharmd-mph

Articles

Site Logo
October 1st 2002

Comparison of the Baseline Cardiovascular Risk Profile Among Hypertensive Patients Prescribed COX-2-Specific Inhibitors or Nonspecific NSAIDs: Data From Real-Life Practice

Sean Z. Zhao, MD, PhD Thomas A. Burke, PharmD, MPH Andrew Whelton, MD, PhD Heather von Allmen Scott C. Henderson, MS

Site Logo
October 1st 2002

Blood Pressure Destabilization and Related Healthcare Utilization Among Hypertensive Patients Using Nonspecific NSAIDs and COX-2-Specific Inhibitors

Sean Z. Zhao, MD, PhD Thomas A. Burke, PharmD, MPH Andrew Whelton, MD, PhD Heather von Allmen Scott C. Henderson, MS

Site Logo
October 1st 2002

Cost of Heart Failure Among Hypertensive Users of Nonspecific NSAIDs and COX-2-Specific Inhibitors

Sean Z. Zhao, MD, PhD Thomas A. Burke, PharmD, MPH Andrew Whelton, MD, PhD Heather von Allmen Scott C. Henderson, MS

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Hurricane | Image credit: Satoshi Kina - stock.adobe.com
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Opdivo packaging | Image credit: Bristol Myers Squibb
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
ICYMI: Highlights From IMS 2024
Published: December 17th 2024 | Updated: December 22nd 2024
ICYMI: Highlights From IMS 2024

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo